

# Mohd Nawaz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5765449/publications.pdf>

Version: 2024-02-01

47  
papers

2,313  
citations

236612

25  
h-index

253896

43  
g-index

48  
all docs

48  
docs citations

48  
times ranked

3488  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proprotein convertase furin is a driver and potential therapeutic target in proliferative diabetic retinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2022, 50, 632-652.	1.3	3
2	Apocynin ameliorates NADPH oxidase 4 (NOX4) induced oxidative damage in the hypoxic human retinal Müller cells and diabetic rat retina. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 2099-2109.	1.4	18
3	CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy. , 2021, 62, 32.		17
4	Tissue Inhibitor of Metalloproteinase-3 Ameliorates Diabetes-Induced Retinal Inflammation. <i>Frontiers in Physiology</i> , 2021, 12, 807747.	1.3	8
5	d-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3. <i>Angiogenesis</i> , 2020, 23, 357-369.	3.7	8
6	Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy. <i>Frontiers in Immunology</i> , 2020, 11, 601639.	2.2	25
7	The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. <i>Cancers</i> , 2019, 11, 1305.	1.7	18
8	Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey?. <i>Diabetes Care</i> , 2019, 42, e105-e106.	4.3	13
9	The Potential Beneficial Effects of Curcumin in Diabetic Retinopathy. , 2019, , 401-417.		0
10	Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. <i>Progress in Retinal and Eye Research</i> , 2019, 72, 100756.	7.3	91
11	N-tert-butylloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. <i>Angiogenesis</i> , 2018, 21, 47-59.	3.7	27
12	Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. <i>Diabetologia</i> , 2017, 60, 719-728.	2.9	33
13	CoFe <sub>2</sub> O <sub>4</sub> ZnO nanoparticles for rapid microwave-assisted tryptic digestion of phosphoprotein and phosphopeptide analysis by matrix-assisted laser desorption/ionization mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 1443-1453.	0.7	3
14	Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. <i>Current Eye Research</i> , 2016, 41, 1590-1600.	0.7	26
15	Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2016, 22, 424-35.	1.1	15
16	Upregulated Expression of Heparanase in the Vitreous of Patients With Proliferative Diabetic Retinopathy Originates From Activated Endothelial Cells and Leukocytes. , 2015, 56, 8239.		33
17	Synthesis, characterization and bifunctional applications of bidentate silver nanoparticle assisted single drop microextraction as a highly sensitive preconcentrating probe for protein analysis. <i>RSC Advances</i> , 2015, 5, 41595-41603.	1.7	38
18	The Tumor Necrosis Factor Superfamily Members TWEAK, TNFSF15 and Fibroblast Growth Factor-Inducible Protein 14 Are Upregulated in Proliferative Diabetic Retinopathy. <i>Ophthalmic Research</i> , 2015, 53, 122-130.	1.0	14

#	ARTICLE	IF	CITATIONS
19	High-Mobility Group Box-1 Modulates the Expression of Inflammatory and Angiogenic Signaling Pathways in Diabetic Retina. <i>Current Eye Research</i> , 2015, 40, 1141-1152.	0.7	33
20	The Angiogenic Biomarker Endocan is Upregulated in Proliferative Diabetic Retinopathy and Correlates with Vascular Endothelial Growth Factor. <i>Current Eye Research</i> , 2015, 40, 321-331.	0.7	30
21	The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood-Retinal Barrier Breakdown. , 2015, 56, 1956.		14
22	Mutual enhancement between high-mobility group box-1 and NADPH oxidase-derived reactive oxygen species mediates diabetes-induced upregulation of retinal apoptotic markers. <i>Journal of Physiology and Biochemistry</i> , 2015, 71, 359-372.	1.3	52
23	Role of high-mobility group box-1 protein in disruption of vascular barriers and regulation of leukocyte-endothelial interactions. <i>Journal of Receptor and Signal Transduction Research</i> , 2015, 35, 340-345.	1.3	23
24	Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy. <i>Lipids in Health and Disease</i> , 2014, 13, 187.	1.2	20
25	The Proinflammatory Cytokine High-Mobility Group Box-1 Mediates Retinal Neuropathy Induced by Diabetes. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	1.4	42
26	Bone morphogenetic protein 2: A potential new player in the pathogenesis of diabetic retinopathy. <i>Experimental Eye Research</i> , 2014, 125, 79-88.	1.2	42
27	S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. <i>Molecular Vision</i> , 2014, 20, 1209-24.	1.1	37
28	Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy. <i>Acta Diabetologica</i> , 2013, 50, 545-551.	1.2	33
29	Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy. <i>Acta Diabetologica</i> , 2013, 50, 363-371.	1.2	34
30	Neurodegeneration and Neuroprotection in Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2559-2572.	1.8	71
31	Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. <i>Experimental Eye Research</i> , 2013, 109, 67-76.	1.2	74
32	Reduced Levels of Brain Derived Neurotrophic Factor (BDNF) in the Serum of Diabetic Retinopathy Patients and in the Retina of Diabetic Rats. <i>Cellular and Molecular Neurobiology</i> , 2013, 33, 359-367.	1.7	89
33	High-Mobility Group Box-1 Induces Decreased Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in the Diabetic Retina. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	1.4	29
34	Angiogenic and Vasculogenic Factors in the Vitreous from Patients with Proliferative Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-9.	1.0	39
35	<a href="http://www.w3.org/1998/Math/MathML">http://www.w3.org/1998/Math/MathML</a> id="M1"><mml:mrow><mml:msub><mml:mrow><mml:mtext>ERK</mml:mtext></mml:mrow><mml:mrow><mml:mn mathvariant="bold-italic">1</mml:mn><mml:mo>/</mml:mo><mml:mn mathvariant="bold-italic">2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math>Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-9.	1.0	23
36	Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2013, 91, e169-77.	0.6	26

#	ARTICLE	IF	CITATIONS
37	Novel drugs and their targets in the potential treatment of diabetic retinopathy. <i>Medical Science Monitor</i> , 2013, 19, 300-308.	0.5	16
38	Neurotrophins and Neurotrophin Receptors in Proliferative Diabetic Retinopathy. <i>PLoS ONE</i> , 2013, 8, e65472.	1.1	36
39	Relationship between Vitreous Levels of Matrix Metalloproteinases and Vascular Endothelial Growth Factor in Proliferative Diabetic Retinopathy. <i>PLoS ONE</i> , 2013, 8, e85857.	1.1	70
40	Osteopontin and Other Regulators of Angiogenesis and Fibrogenesis in the Vitreous from Patients with Proliferative Vitreoretinal Disorders. <i>Mediators of Inflammation</i> , 2012, 2012, 1-8.	1.4	39
41	High-Mobility Group Box-1 and Endothelial Cell Angiogenic Markers in the Vitreous from Patients with Proliferative Diabetic Retinopathy. <i>Mediators of Inflammation</i> , 2012, 2012, 1-7.	1.4	34
42	Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. <i>Journal of Diabetes and Its Complications</i> , 2012, 26, 56-64.	1.2	143
43	Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. <i>Molecular and Cellular Biochemistry</i> , 2011, 351, 41-58.	1.4	742
44	High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2011, 89, 0-0.	0.6	3
45	High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. <i>Molecular Vision</i> , 2011, 17, 1829-38.	1.1	85
46	Two-step on-particle ionization/enrichment via a washing- and separation-free approach: multifunctional TiO <sub>2</sub> nanoparticles as desalting, accelerating, and affinity probes for microwave-assisted tryptic digestion of phosphoproteins in ESI-MS and MALDI-MS: comparison with microscale TiO <sub>2</sub> . <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2909-2919.	1.9	32
47	Surface-modified TiO <sub>2</sub> nanoparticles as affinity probes and as matrices for the rapid analysis of phosphopeptides and proteins in MALDI-TOF-MS. <i>Journal of Separation Science</i> , 2010, 33, 3400-3408.	1.3	12